Literature DB >> 6931507

Human preleukemia.

H P Koeffler, D W Golde.   

Abstract

Preleukemia refers to the syndrome of hematopoietic dysfunction seen in some patients before typical features of acute myelogenous leukemia develop. Clinically, preleukemia is characterized by variable degrees of pancytopenia, with associated symptoms due to decreased circulating blood elements. The bone marrow is usually hypercellular, and there are prominent morphologic abnormalities in erythroid precursors and more subtle changes in megakaryocytes and granulocyte progenitors. During this phase of the leukemic process, the neoplastic clone is usually already established and predominant. A clear distinction should be made between the preleukemic syndrome and diseases that predispose to development of acute myelogenous leukemia. Preleukemia, like acute myelogenous leukemia, is a clonal hematopoietic stem cell neoplasm manifested functionally by abnormal hematopoietic cell maturation and ineffective hematopoiesis. During the course of preleukemia, precursor cell maturation becomes progressively impaired with termination in the severe maturational block characteristic of acute myelogenous leukemia. We favor the concept that preleukemia is an early phase of acute myelogenous leukemia.

Entities:  

Mesh:

Year:  1980        PMID: 6931507     DOI: 10.7326/0003-4819-93-2-347

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  15 in total

1.  Partial splenic embolization in myelodysplastic syndrome associated with immune thrombocytopenia.

Authors:  Hakan Ozdogu; Can Boga; Levent Oğuzkurt; Ebru Kizilkilic
Journal:  J Thromb Thrombolysis       Date:  2004-12       Impact factor: 2.300

2.  Evolution of multiple cytogenetic clones and leukemic transformation in a case of myelodysplastic syndrome.

Authors:  E Donti; G V Donti; F Falzetti; A Rosetti; F Grignani; A Tabilio
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  CD4 deficiency in myelodysplastic syndrome with monosomy 7.

Authors:  C M Weemaes; F Preijers; G A de Vaan; J A Bakkeren; I S Klasen; A Haraldsson
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

4.  Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts.

Authors:  G Kerndrup; B Pedersen; J Ellegaard; P Hokland
Journal:  Blut       Date:  1986-01

5.  Treatment of therapy-induced preleukemic syndrome.

Authors:  M Gyger; C Perreault; J Carnot; J Boileau; Y Bonny
Journal:  Blut       Date:  1984-02

6.  Idiopathic refractory sideroachrestic anemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukemia. Case report and review of the literature.

Authors:  R Hehlmann; B Zönnchen; E Thiel; B Walther
Journal:  Blut       Date:  1983-01

Review 7.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

Review 8.  Bone biopsy in haematological disorders.

Authors:  R Burkhardt; B Frisch; R Bartl
Journal:  J Clin Pathol       Date:  1982-03       Impact factor: 3.411

Review 9.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

10.  Granulocyte Fc-IgG and C3b receptor expression in the primary myelodysplastic syndromes (MDS): relationship with dysgranulopoiesis and evidence for heterogeneity of morphological subgroups.

Authors:  A G Bynoe; C S Scott; D Hough; B E Roberts
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.